Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice

The combined glucose-lowering effect of exenatide and dapagliflozin has not yet been studied. We investigated this combination (single-dose or 4-week dosing) in diabetic ob/ob mice. Vehicle-corrected basal glucose showed greater reduction 1 h following exenatide + dapagliflozin than with exenatide o...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Diabetes Obes Metab
Asıl Yazarlar: Tatarkiewicz, K, Polizzi, C, Villescaz, C, D’Souza, L J, Wang, Y, Janssen, S, Parkes, D G
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Publishing Ltd 2014
Konular:
Research Letter
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4237538/
https://ncbi.nlm.nih.gov/pubmed/24251534
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12237
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller